Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical and the Takeda Oncology Company: Millennium, have commenced TRINOVA-1 Phase III clinical trial on anti-cancer agent AMG 386 in Japan.
Subscribe to our email newsletter
TRINOVA-1 is a global multicenter, randomized, double-blind trial of paclitaxel plus AMG 386 or placebo in women with recurrent ovarian cancer.
Discovered by Amgen, the cancer agent targets the angiopoietin axis and blocks the interactions between angiopoietins -1 and -2 (Ang1 and Ang2) and their receptor Tie2.
The primary endpoint of the trial is progression-free survival.
Millennium chief medical officer Nancy Simonian said advancement to Phase III clinical trials is a huge step forward in the development of AMG 386.
"These patients have very limited treatment options and we are excited by the potential of this compound to alleviate this need in ovarian cancer," Simonian said.